25 September, 2020
The regulatory approval and commercialisation of Luxturna in 2017 has opened the floodgates for gene therapy, with numerous clinical trials underway or rapidly approaching. Dr Tom Edwards and Dr Lauren Ayton will update Retina Australia members on the national approach to identifying and characterising people who might be eligible for these trials (through the Inherited Retinal Disease Natural History Study), as well as describing the most promising developments in the field.
This webinar will take place on Saturday 17th October at 2:00pm EST. You can find a copy of the flyer in Word version here or in PDF version here
https://retinaaustralia.com.au/webinar-event-gene-therapy-clinical-trials-and-new-developments-in-ird-research/
Other News
Inaugural Message from CEO Jonathan Brookes.
I am thrilled to write to you as the new CEO of Retina Australia. It has been an exciting...
Retina Australia appoints Jonathan Brookes as new CEO.
Retina Australia, the national organisation committed to progressing its vision of “a world without...
2026 Research Grants awarded
The Board of Retina Australia is delighted to announce two new Research Grants awarded for 2026. Associate Professor Raymond Wong, from the Centre for Eye...